Floatz logo

PATIDEGIB

Recurrent Basal Cell Carcinoma

Sol-Gel Technologies, Ltd.Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Recurrent Basal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Liposomal T4N5 Lotion
National Cancer Institute (NCI)
Phase 2B
L19IL2/L19TNF
Philogen S.p.A.
Phase 2CCC
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 1/2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 1/2CCC

View all 21 →

Same molecule, other indications

PATIDEGIB is also rated in:

malignant pancreatic neoplasmDormant
CC
Indicative ·
46 / 100
View asset →
adenocarcinomaDormant
CC
Indicative ·
46 / 100
View asset →
neoplasmDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →